Inovio Pharmaceuticals, Inc.
INO
$2.05
$0.105.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 283.10K | 217.80K | 203.50K | 591.90K | 717.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 283.10K | 217.80K | 203.50K | 591.90K | 717.10K |
| Cost of Revenue | 70.80M | 75.62M | 79.99M | 76.76M | 75.43M |
| Gross Profit | -70.52M | -75.41M | -79.79M | -76.17M | -74.71M |
| SG&A Expenses | 35.45M | 36.99M | 34.94M | 36.25M | 39.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 106.25M | 112.62M | 114.93M | 113.01M | 114.99M |
| Operating Income | -105.96M | -112.40M | -114.72M | -112.42M | -114.28M |
| Income Before Tax | -96.48M | -107.25M | -112.88M | -121.64M | -124.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -96.48 | -107.25 | -112.88 | -121.64 | -124.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.48M | -107.25M | -112.88M | -121.64M | -124.94M |
| EBIT | -105.96M | -112.40M | -114.72M | -112.42M | -114.28M |
| EBITDA | -104.27M | -110.65M | -112.82M | -110.29M | -111.87M |
| EPS Basic | -3.24 | -4.03 | -4.49 | -5.11 | -5.54 |
| Normalized Basic EPS | -2.03 | -2.53 | -2.71 | -2.79 | -2.98 |
| EPS Diluted | -3.24 | -4.04 | -4.49 | -5.11 | -5.54 |
| Normalized Diluted EPS | -2.03 | -2.53 | -2.71 | -2.79 | -2.98 |
| Average Basic Shares Outstanding | 123.94M | 108.62M | 101.36M | 95.61M | 90.44M |
| Average Diluted Shares Outstanding | 123.94M | 108.62M | 101.36M | 95.61M | 90.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |